Investors & Media

What's new.

E-Mail

registration.

Please fill in ...

Please add 9 and 5.

 

Press releases

Press releases.

Immutep Announces Abstract Accepted for Mini Oral Presentation at ESMO’s European Lung Cancer Congress 2023

March 23rd 2023
press releases

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

March 14th 2023
press releases

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

February 6th 2023
press releases
more

Investor updates

Investor updates.

Investor Update - November 2022

November 17th 2022
investor updates

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates

Investor Update - February 2022

February 18th 2022
investor updates
more

Analyst reports

Analyst reports.

Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

March 14th 2023
analyst reports

CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

March 7th 2023
analyst reports

Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

February 28th 2023
analyst reports
more